The global point-of-care diagnostics market revenue was around US$ 39.4 billion in 2022 and is estimated to reach US$ 98.3 billion by 2031, growing at a compound annual growth rate (CAGR) of 10.7% during the forecast period from 2023 to 2031.
Point-of-care (POC) diagnostic devices are medical equipment that is implied in the POC procedure. In this, various diseases, such as diabetes, cancer, heart disease, and others, are referred to as point-of-care (POC) diagnostic devices. They enable medical practitioners to identify and treat these medical disorders by examining the causes of diseases. These devices are becoming more popular among professionals as they offer rapid diagnosis results and immediate guidance for precise therapy.
Market Driving Factors
Regional Analysis
Europe is anticipated to grow at a significant CAGR throughout the forecast period. Major players in this region are concentrating on the development of rapid diagnostic instruments for the prompt diagnosis of infectious diseases. The government has also made R&D funding to aid the diagnostics sector in developing the most advanced point-of-care diagnostic tests. These components aid in the market's expansion in this region.
Segmentation Insights
End User Insights
The home care segment is predicted to have the greatest CAGR during the projection period. This is due to the end customers are patients and first responders who utilize monitoring devices in residential settings. Blood pressure monitors, Blood glucose meters, pregnancy test kits, HIV test kits, and test kits for respiratory diseases are among the equipment widely used in this segment. The ease of use of home testing kits is one of the key factors contributing to their increasing popularity. Their lower price and increased availability are further significant factors.
Platform Insights
The lateral flow assay segment is expected to grow quickly due to the quick adoption of LFA testing products in home care settings, and the rise in focus of market players on developing cutting-edge LFA-based point-of-care devices. In addition, growing awareness of the advantages of lateral flow assay-based point-of-care tests as an alternative to expensive laboratory tests and the reduced expenses associated with this method over traditional laboratory procedures.
Prominent Companies
Segmentation Outline
The global point of care diagnostics market segmentation focuses on Product Type, End Users, Platform, and Region.
By Product Type
By End Users
By Platform
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: POINT-OF-CARE DIAGNOSTICS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 GLUCOSE TESTING
5.2.1 HB1AC TESTING
5.2.2 COAGULATION TESTING
5.3 FERTILITY/PREGNANCY
5.4 INFECTIOUS DISEASE
5.4.1 HIV POC
5.4.2 CLOSTRIDIUM DIFFICILE POC
5.4.3 HBV POC
5.4.4 PNEUMONIA OR STREPTOCOCCUS ASSOCIATED INFECTIONS
5.4.5 RESPIRATORY SYNCYTIAL VIRUS (RSV) POC
5.4.6 HPV POC
5.4.7 INFLUENZA/FLU POC
5.4.8 HCV POC
5.4.9 MRSA POC
5.4.10 TB
5.4.11 DRUG-RESISTANT TB POC
5.4.12 HSV POC
5.4.13 COVID-19
5.4.14 OTHER
5.5 CARDIAC MARKERS
5.6 THYROID STIMULATING HORMONE
5.7 HAEMATOLOGY
5.8 PRIMARY CARE SYSTEMS
5.9 DECENTRALIZED CLINICAL CHEMISTRY
5.10 FAECES
5.11 LIPID TESTING
5.12 CANCER MARKER
5.13 BLOOD GAS/ELECTROLYTES
5.14 AMBULATORY CHEMISTRY
5.15 DRUG OF ABUSE (DOA) TESTING
5.16 URINALYSIS/NEPHROLOGY
6 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY END USERS
6.1 OVERVIEW
6.2 CLINICS
6.3 HOSPITALS
6.4 HOMECARE
6.5 ASSISTED LIVING HEALTHCARE FACILITIES
6.6 LABORATORY
7 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM
7.1 OVERVIEW
7.2 LATERAL FLOW ASSAY
7.3 DIPSTICKS
7.4 MICROFLUIDICS
7.5 MOLECULAR DIAGNOSTICS
7.6 IMMUNOASSAYS
8 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 ABBOTT LABORATORIES
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 ROCHE DIAGNOSTICS
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 SIEMENS HEALTHINEERS AG
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 DANAHER CORPORATION
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 BECTON, DICKINSON AND COMPANY
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 QUIDEL CORPORATION
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 BIOMÉRIEUX SA
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 SYSMEX CORPORATION
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 NOVA BIOMEDICAL CORPORATION
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 TRINITY BIOTECH PLC
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 HOLOGIC, INC.
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 SEKISUI DIAGNOSTICS, LLC
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.13 EKF DIAGNOSTICS HOLDINGS PLC
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.14 PTS DIAGNOSTICS
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.15 CHEMBIO DIAGNOSTIC SYSTEMS INC
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.16 ORASURE TECHNOLOGIES INC
10.16.1 OVERVIEW
10.16.2 FINANCIAL PERFORMANCE
10.16.3 PRODUCT OUTLOOK
10.16.4 KEY DEVELOPMENTS
10.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.17 BIO-RAD LABORATORIES INC
10.17.1 OVERVIEW
10.17.2 FINANCIAL PERFORMANCE
10.17.3 PRODUCT OUTLOOK
10.17.4 KEY DEVELOPMENTS
10.17.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.18 LUMIRADX
10.18.1 OVERVIEW
10.18.2 FINANCIAL PERFORMANCE
10.18.3 PRODUCT OUTLOOK
10.18.4 KEY DEVELOPMENTS
10.18.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.19 MAGNASENSE TECHNOLOGIES
10.19.1 OVERVIEW
10.19.2 FINANCIAL PERFORMANCE
10.19.3 PRODUCT OUTLOOK
10.19.4 KEY DEVELOPMENTS
10.19.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.20 SPECTRAL MEDICAL INC
10.20.1 OVERVIEW
10.20.2 FINANCIAL PERFORMANCE
10.20.3 PRODUCT OUTLOOK
10.20.4 KEY DEVELOPMENTS
10.20.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved